Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T de Witte

Showing results (191-200 of 215) with videos related to

Pageof 22
Sort By:
Leukemia|August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia GroupsS Amadori, S Suciu, R Stasi, et al.
Blood|May 29, 2000
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationC Guglielmi, W Arcese, J Hermans, et al.
Leukemia|April 3, 2009
The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domainsJ A Marteijn, L T van der Meer, J J Smit, et al.
Bone Marrow Transplantation|July 9, 2009
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009P Ljungman, M Bregni, M Brune, et al.
Blood|April 27, 1999
Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative StudyP Guardiola, J E Anderson, G Bandini, et al.
Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.
Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.
Leukemia|August 13, 2010
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registryM Michallet, M Sobh, D Milligan, et al.
Blood|November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.
Bone Marrow Transplantation|May 1, 2012
The EBMT activity survey: 1990-2010J R Passweg, H Baldomero, A Gratwohl, et al.
Pageof 22

Showing results (191-200 of 215) with videos related to

Sort By:
Pageof 22
Leukemia|August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia GroupsS Amadori, S Suciu, R Stasi, et al.
Blood|May 29, 2000
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationC Guglielmi, W Arcese, J Hermans, et al.
Leukemia|April 3, 2009
The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domainsJ A Marteijn, L T van der Meer, J J Smit, et al.
Bone Marrow Transplantation|July 9, 2009
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009P Ljungman, M Bregni, M Brune, et al.
Blood|April 27, 1999
Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative StudyP Guardiola, J E Anderson, G Bandini, et al.
Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.
Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.
Leukemia|August 13, 2010
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registryM Michallet, M Sobh, D Milligan, et al.
Blood|November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.
Bone Marrow Transplantation|May 1, 2012
The EBMT activity survey: 1990-2010J R Passweg, H Baldomero, A Gratwohl, et al.
Pageof 22